Connecting Hope and
Medical Science
    

      
 

CCRP Clinical Trials

Click here for Physician Area

Only show trials for the disease site :

DiseaseSiteProtocolNumberStatusTitle
BoneS0702 (CTSU/SWOG)CLOSED TO ACCRUALA Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid treatment.
BrainRTOG-1205OPENRandomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
BrainN107C (CTSU/NCCTG)OPENA Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease.
BrainN0577 (CTSU/NCCTG)OPENPhase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma.
BrainRTOG-0925OPENNatural History of Postoperative Cognitive Function, Quality of Life and Seizure Control in Patients with Supratentorial Low-Risk Grade II Glioma.
BrainE3F05SUSPENDEDPhase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas.
BrainN0872CLOSED TO ACCRUALPhase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma.
BreastB-39CLOSED TO ACCRUALA Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
BreastB-42CLOSED TO ACCRUALA Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.
BreastB-41CLOSED TO ACCRUALA Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response.
12345678910...